By Hybridon Hybridon is a leader in the development of oligonucleotide chemistries for therapeutics and diagnostics. These platforms allow Hybridon to create value through a combination of in-house development of products, collaborations with partners and the licensing of broadly applicable technology. Inc. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and financing such activities. Actual results could differ materially from those projected in this release. As a result, the reader is cautioned not to rely on these forward-looking statements.
Copies are available from the respective companies.
The lab tests have confirmed earlier finding that, in synergy with antibiotics, rBPI21 can rapidly kill common ocular pathogens. This confirmation was considered as a first proof of concept that Xoma s product could be the element of hope in treating antibiotic-resistant eye infections. XOMA and Allergan have decided to move forward in developing the compound as a therapeutic for eye infection. Allergan was convinced that this host protein will play a major role in saving eyes from the resistant bacteria, a problem that is the nightmare of ophthalmologists. In many cases, ophthalmologists are helpless, feeling desperate, while watching all kind of antibiotics fail to save a deteriorating eye that is victimized by stubborn microbes.